Dominik Dytfeld
A5016144961- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Lymphoma Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Cell death mechanisms and regulation
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Advanced Proteomics Techniques and Applications
- Cancer Mechanisms and Therapy
- Cancer therapeutics and mechanisms
- Hematopoietic Stem Cell Transplantation
- Insect Resistance and Genetics
- Acute Lymphoblastic Leukemia research
- Nuclear Structure and Function
- Research on Leishmaniasis Studies
- Malaria Research and Control
- Cancer-related Molecular Pathways
- Phytochemical compounds biological activities
- Venous Thromboembolism Diagnosis and Management
Poznan University of Medical Sciences
2016-2025
Veterans Health Administration
2023
Janssen (United States)
2023
Janssen Scientific Affairs (United States)
2023
University of Chicago Medical Center
2020
University Hospital of Lord’s Transfiguration
2020
Vrije Universiteit Brussel
2019
Szpital Kliniczny Nr 1 we Wrocławiu
2018
Authorised Association Consortium
2016
University of Illinois Chicago
2013-2015
The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. immunomodulatory agent pomalidomide myeloma that is a proteasome inhibitor.Patients was inhibitor were randomly assigned receive (elotuzumab group) alone (control group). primary end point investigator-assessed progression-free survival.A total of 117 the group (60 patients) control (57 patients). After minimum...
Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel earlier treatment lines lenalidomide-refractory disease. Download PDF of the Research Summary. In this phase 3, randomized, open-label trial, we assigned myeloma to receive physician's choice standard care. All had received one three previous treatment. The primary outcome was...
Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life care (SOC) in triple-class exposed (received at least a PI, IMiD, mAb) relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status 0-1, ≥3 prior lines...
In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus (Pd) in patients relapsed/refractory multiple myeloma (RRMM) previously treated lenalidomide and a proteasome inhibitor (PI). Here, we present final overall (OS) results.Patients RRMM who had received ≥ 2 prior lines of therapy, disease refractory to last therapy either or relapsed PI were...
// Ravyn M. Thompson 1 , Dominik Dytfeld 2 Leticia Reyes Reeder Robinson Brittany Smith Yefim Manevich Andrzej Jakubowiak 3 Mieczyslaw Komarnicki Anna Przybylowicz-Chalecka Tomasz Szczepaniak Amit K. Mitra 5 Brian G. Van Ness Magdalena Luczak 4 Nathan Dolloff 1, * Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University South Carolina, Charleston, SC, USA Karol Marcinkowski Sciences, Poznan, Poland Chicago, IL, Institute Bioorganic Chemistry, Polish...
// Dominik Dytfeld 1, 9, * , Magdalena Luczak 2, 11, Tomasz Wrobel 3, Lidia Usnarska-Zubkiewicz 3 Katarzyna Brzezniakiewicz 9 Krzysztof Jamroziak 5, Giannopoulos 6, Anna Przybylowicz-Chalecka 1 Blazej Ratajczak Joanna Czerwinska-Rybak Adam Nowicki Monika Joks Elzbieta Czechowska 7, Zawartko 8 Szczepaniak Norbert Grzasko Marta Morawska Maciej Bochenek Tadeusz Kubicki Michalina 4, Tusznio 5 Andrzej Jakubowiak 10 Mieczysław Komarnicki Department of Hematology and Bone Marrow Transplantation,...
Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on basis results from phase I/II MonumenTAL-1 trial. The relative effectiveness talquetamab vs. real-world physician's choice therapy (RWPC) was assessed using adjusted comparisons. An external control arm (subcutaneously administered 0.4 mg/kg weekly [QW] and 0.8 every other week [Q2W]) created two observational...
Exportin1 (XPO1; also known as chromosome maintenance region 1, or CRM1) controls nucleo-cytoplasmic transport of most tumor suppressors and is overexpressed in many cancers, including multiple myeloma, functionally impairing suppressive function via target mislocalization. Selective inhibitor nuclear export (SINE) compounds block XPO1-mediated escape by disrupting cargo protein binding, leading to retention suppressors, induction cancer cell death, sensitization other drugs. Combined...
Background/Aim: Cryopreservation of allogeneic hematopoietic cells can be an necessary step in the preparation a graft for transplantation. The purpose this study was to evaluate safety cryopreservation and clinical outcomes patients who received cryopreserved transplant. Patients Methods: included data from comparative analysis conducted on group 100 diagnosed with acute myeloid leukemia (50 patients) fresh transplants. Both quantitative qualitative parameters grafts were evaluated, as well...
The number of newly diagnosed haematological malignancies in Polish adults and children is about 9,000 a year, which constitutes 5.5% all the country. Adult patients with are treated 42 institutions Poland. scientific educational support for this activity provided under umbrella Society Haematologists Transfusiologists (PTHiT, Polskie Towarzystwo Hematologów i Transfuzjologów ), Leukemia Group (PALG), Lymphoma Research (PLRG), Myeloma Study (PMSG), Consortium (PMC), consultants haematology....